Newer Drugs for Tuberculosis Prevention and Treatment in Children

Overview

Journal Indian J Pediatr

Specialty Pediatrics

Date 2019 Feb 2

PMID 30707347

Citations 5

Authors

Ben J Marais

Affiliations

Soon will be listed here.

Abstract

Children suffer a huge and often an unrecognized burden of tuberculosis (TB) in endemic countries like India. Better data have improved the visibility of childhood TB, but the establishment of functional TB prevention and treatment programs for children remains challenging. Barriers to TB prevention include: 1) non-implementation of existing guidelines, 2) perceived inability to rule out active TB with fear of creating drug resistance and 3) limited local guidance on the use of preventive therapy after close contact with drug resistant TB. Barriers to TB treatment include: 1) diagnostic challenges in resource-limited settings, 2) presentation to maternal and child health (MCH) services with poor linkage to the TB control program and 3) limited local guidance on the treatment of children with likely drug resistant TB. The authors provide an overview of newer drugs used for TB prevention and treatment in children. They discuss new options for the treatment of latent TB infection (LTBI) and new or repurposed drugs used in the treatment of children with multidrug resistant (MDR)-TB. The background information provided describes the benefits, risks and feasibility of various treatment options, which should assist treatment decisions until updated World Health Organization (WHO) guidance becomes available.

Citing Articles

Holistic acceptability of an adult levofloxacin formulation in children and adolescents on a tuberculosis preventive treatment trial.

Purchase S, Wademan D, Tshetu N, Rafique M, Hoddinott G, Seddon J PLOS Glob Public Health. 2024; 4(7):e0003381.

PMID: 38968182 PMC: 11226063. DOI: 10.1371/journal.pgph.0003381.

Toward a conceptual framework of the acceptability of tuberculosis treatment in children using a theory generative approach.

Wademan D, Palmer M, Purchase S, van der Zalm M, Osman M, Garcia-Prats A PLOS Glob Public Health. 2023; 2(12):e0001267.

PMID: 36962908 PMC: 10021666. DOI: 10.1371/journal.pgph.0001267.

Practical and psychosocial challenges faced by caregivers influence the acceptability of multidrug-resistant tuberculosis preventive therapy for young children.

Wademan D, Hoddinott G, Purchase S, Seddon J, Hesseling A, Garcia-Prats A PLoS One. 2022; 17(7):e0268560.

PMID: 35834509 PMC: 9282439. DOI: 10.1371/journal.pone.0268560.

Challenging drug-resistant TB treatment journey for children, adolescents and their care-givers: A qualitative study.

Das M, Mathur T, Ravi S, Meneguim A, Iyer A, Mansoor H PLoS One. 2021; 16(3):e0248408.

PMID: 33690715 PMC: 7946226. DOI: 10.1371/journal.pone.0248408.

Advances in Tuberculosis: Therapeutics.

Singh V, Kabra S Indian J Pediatr. 2019; 86(8):700-702.

PMID: 31209764 DOI: 10.1007/s12098-019-03005-3.

References

Pandie M, Wiesner L, McIlleron H, Hughes J, Siwendu S, Conradie F . Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. J Antimicrob Chemother. 2016; 71(4):1037-40. DOI: 10.1093/jac/dkv447. View

Dodd P, Sismanidis C, Seddon J . Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis. 2016; 16(10):1193-1201. DOI: 10.1016/S1473-3099(16)30132-3. View

Bamrah S, Brostrom R, Dorina F, Setik L, Song R, Kawamura L . Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Int J Tuberc Lung Dis. 2014; 18(8):912-8. PMC: 4730114. DOI: 10.5588/ijtld.13.0028. View

. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis. 1992; 145(1):36-41. DOI: 10.1164/ajrccm/145.1.36. View

Spyridis N, Spyridis P, Gelesme A, Sypsa V, Valianatou M, Metsou F . The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007; 45(6):715-22. DOI: 10.1086/520983. View

Sharma S, Sharma A, Kadhiravan T, Tharyan P . Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev. 2013; (7):CD007545. PMC: 6532682. DOI: 10.1002/14651858.CD007545.pub2. View

Dodd P, Yuen C, Sismanidis C, Seddon J, Jenkins H . The global burden of tuberculosis mortality in children: a mathematical modelling study. Lancet Glob Health. 2017; 5(9):e898-e906. PMC: 5556253. DOI: 10.1016/S2214-109X(17)30289-9. View

Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P . Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017; 17(1):265. PMC: 5387294. DOI: 10.1186/s12879-017-2377-x. View

Johnson K, Churchyard G, Sohn H, Dowdy D . Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings. Clin Infect Dis. 2018; 67(7):1072-1078. DOI: 10.1093/cid/ciy230. View

10.

Perez-Velez C, Roya-Pabon C, Marais B . A systematic approach to diagnosing intra-thoracic tuberculosis in children. J Infect. 2017; 74 Suppl 1:S74-S83. DOI: 10.1016/S0163-4453(17)30195-0. View

11.

Svensson E, Dooley K, Karlsson M . Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. Antimicrob Agents Chemother. 2014; 58(11):6406-12. PMC: 4249405. DOI: 10.1128/AAC.03246-14. View

12.

Jenkins H, Tolman A, Yuen C, Parr J, Keshavjee S, Perez-Velez C . Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet. 2014; 383(9928):1572-9. PMC: 4094366. DOI: 10.1016/S0140-6736(14)60195-1. View

13.

Diacon A, Pym A, Grobusch M, de los Rios J, Gotuzzo E, Vasilyeva I . Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014; 371(8):723-32. DOI: 10.1056/NEJMoa1313865. View

14.

Jenkins H, Yuen C, Rodriguez C, Nathavitharana R, McLaughlin M, Donald P . Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2016; 17(3):285-295. PMC: 5330933. DOI: 10.1016/S1473-3099(16)30474-1. View

15.

Sterling T, Scott N, Miro J, Calvet G, La Rosa A, Infante R . Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS. 2016; 30(10):1607-15. PMC: 4899978. DOI: 10.1097/QAD.0000000000001098. View

16.

Ena J, Valls V . Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis. 2005; 40(5):670-6. DOI: 10.1086/427802. View

17.

Lachatre M, Rioux C, Le Du D, Frechet-Jachym M, Veziris N, Bouvet E . Bedaquiline plus delamanid for XDR tuberculosis. Lancet Infect Dis. 2016; 16(3):294. DOI: 10.1016/S1473-3099(16)00047-5. View

18.

Sterling T, Villarino M, Borisov A, Shang N, Gordin F, Bliven-Sizemore E . Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011; 365(23):2155-66. DOI: 10.1056/NEJMoa1104875. View

19.

Jindani A, Harrison T, Nunn A, Phillips P, Churchyard G, Charalambous S . High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014; 371(17):1599-608. PMC: 4233406. DOI: 10.1056/NEJMoa1314210. View

20.

Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Baah J . Safety and Side Effects of Rifampin versus Isoniazid in Children. N Engl J Med. 2018; 379(5):454-463. DOI: 10.1056/NEJMoa1714284. View